Kary Eldred, Director of Galectin Therapeutics GALT, has filed 12 purchases and 0 sales on the open market. Over the past 12 months that comes to a net purchase of $6,032. The latest trade was on 02/06.

KE

KE

Kary Eldred

Director

Company

Galectin Therapeutics GALT

First filing

23/02/21

Trades

16 trades

Buys / sales

12 / 0

12-month net buying

$6,032

Last trade

02/06

FollowShare

Trading activity

6 months1 year2 years5 yearsAll

Transactions

Company	Trade type	Traded	Filed	Shares	Price	Value	Holding change
Galectin TherapeuticsGALT	Open-market buy	02/06	02/09	300 sh	$2.70	$810	+0.5%
Galectin TherapeuticsGALT	Open-market buy10b5-1 plan	25/12/23	25/12/23	1,400 sh2 trades	$3.73avg.	$5,222	+2.2%
Galectin TherapeuticsGALT	Open-market buy	25/07/21	25/07/22	1,000 sh	$2.93	$2,930	+1.6%
Galectin TherapeuticsGALT	Open-market buy	24/12/24	24/12/26	13,469 sh	$0.82	$11,044.58	+26.8%
Galectin TherapeuticsGALT	Open-market buy	24/10/23	24/10/23	500 sh	$2.60	$1,300	+1.0%
Galectin TherapeuticsGALT	Open-market buyAmendment	24/01/16–24/07/22	24/07/23	800 sh2 trades	$2.39avg.	$1,912	+1.6%
Galectin TherapeuticsGALT	Open-market buy	24/01/16	24/01/16	500 sh	$1.79	$895	+1.0%
Galectin TherapeuticsGALT	Open-market buy	23/07/19	23/07/20	1,598 sh	$1.79	$2,860.42	+3.4%
Galectin TherapeuticsGALT	Open-market buy	23/02/21	23/02/21	1,000 sh	$1.59	$1,590	+2.2%
Galectin TherapeuticsGALT	Open-market buy	23/01/25	23/01/26	1,300 sh	$1.11	$1,443	+2.9%